Acadia Pharmaceuticals Inc
Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results
- Third quarter GAAP total revenues of $342 million, up 22% year-over-year as compared to non-GAAP adjusted total revenues
Company newsroom
NASDAQ:ACAD
1 releases
- Third quarter GAAP total revenues of $342 million, up 22% year-over-year as compared to non-GAAP adjusted total revenues